TD Cowen analyst Joseph Thome has maintained their bullish stance on VRDN stock, giving a Buy rating on April 23.
Joseph Thome has given his Buy rating due to a combination of factors that highlight Viridian Therapeutics’ promising outlook. The company is on track with its regulatory submissions for veligrotug, with a Biologics License Application (BLA) expected in the second half of 2025 and a Marketing Authorization Application (MAA) in the first half of 2026. This timeline follows successful Phase III trials in treating Thyroid Eye Disease (TED), positioning the company well for future commercial launches.
Additionally, Viridian’s pipeline includes promising developments in FcRn inhibitors, with VRDN-006 and VRDN-008 showing potential in early trials. The expected data releases in the coming quarters could further solidify the company’s standing in this expanding market. Despite some regulatory uncertainties, the strong data package for veligrotug and recent positive opinions for similar treatments provide a favorable outlook for approval, supporting the Buy rating.
According to TipRanks, Thome is a 3-star analyst with an average return of 0.8% and a 38.50% success rate. Thome covers the Healthcare sector, focusing on stocks such as Alkermes, uniQure, and Axsome Therapeutics.
In another report released on April 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target.